Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis of LNCaP wildtype (WT) and LNCaP OR51E2-knock out xenograft mouse tumor tissue

ABSTRACT: Quantitative proteomic analysis of tumor tissue lysates from wildtype LNCaP (WT) and LNCaP OR51E2-/- (KO) xenografts in male CIEA NOG mice.

INSTRUMENT(S): Orbitrap Eclipse

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Prostate Cancer Cell Line

DISEASE(S): Prostate Cancer

SUBMITTER: Sharon Pitteri

LAB HEAD: Sharon Pitteri

PROVIDER: PXD055974 | Pride | 2025-03-26

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Key.xlsx	Xlsx
	Mikkel_01_Shotgun_01.raw	Raw
	Mikkel_01_Shotgun_01.raw_20220907_Byonic_database.xlsx	Xlsx
	Mikkel_01_Shotgun_01.raw_20220909_Byonic_database.xlsx	Xlsx
	Mikkel_01_Shotgun_02.raw	Raw

Items per page:

1 - 5 of 156

Publications

The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors.

Thomsen Mikkel Thy MT Busk Morten M Zhang Dalin D Chiu Chun-Lung CL Zhao Hongjuan H Garcia-Marques Fernando Jose FJ Bermudez Abel A Pitteri Sharon S Borre Michael M Brooks James D JD Nyengaard Jens Randel JR

BMC cancer 20250324 1

<h4>Background</h4>Despite advancements in the detection and treatment of prostate cancer, the molecular mechanisms underlying its progression remain unclear. This study aimed to investigate the role of the receptor OR51E2, which is commonly upregulated in prostate cancer, in the progression of this disease.<h4>Methods</h4>We investigated the physiological effects of OR51E2 through CRISPR-Cas9-induced monoclonal OR51E2 knockout. We assessed in vitro and in vivo tumorigenicity and conducted trans ...[more]

PMID: 40128715

Similar Datasets

Proteomics Analysis of Trop2 Xenograft Prostate Tumors

Project description:Shotgun proteomic analysis of LNCaP-Trop2-OV tumor xenografts and LNCaP-RFP control tumors

2023-01-05 | PXD039272 | Pride

LNCAP xenograft prostate cancer progression model in NOD-SCID mice

Project description:Xenografts are useful in vivo tumour models for investigating cancer progression, therapeutic responses and predicting anti-cancer drug response in patients with cancer of a similar phenotype. We have generated bulk RNA-seq data from LNCaP xenografts of a large and well-annotated prostate cancer progression study, investigating responsiveness and subsequent resistance to therapies targeting the androgen receptor (AR). LNCaP xenograft tumour establishment and initial growth are dependent on androgens in male mice (PRE-CX / pre-castration group). Upon castration, AR activity and tumour growth are suppressed (POST-CX / post-castration group), however, this initial responsiveness to castration reproducibly gives way to castration-resistance (CRPC / castration-resistant prostate cancer). Further treatment of CRPC with the AR targeting drug enzalutamide (ENZ) initially provides a therapeutic response (ENZ Sensitive; ENZS), however, resistance emerges in time (ENZ Resistant; ENZR).

2022-09-07 | GSE211856 | GEO

Expression data from uncastrasion and castration tumor from LNCAP Orhotopic xenograft models of prostate cancer

2013-04-20 | GSE46218 | GEO

A four-arm study of A375 melanoma cell line-derived xenograft tumors in NSG mice treated with Vemurafenib and CB839

Project description:Melanoma is a rare but deadly form of skin cancer, which is often treated with BRAF inhibitors such as Vemurafenib (referred to as PLX4032). Whilst Vemurafenib prolongs the survival of patients, BRAF inhibitor resistance inevitably occurs in most cases. Previous studies demonstrated that metabolic rewiring occurs in BRAF inhibitor resistance and causes dependence on glutamine. To investigate whether this vulnerability could be exploited with clinically relevant drugs, we used the BRAF inhibitor, Vemurafenib, and the glutaminase imhibitor, CB839 to treat A375-derived melanoma xenografted tumors. We showed that whilst CB839 did not significantly affect the growth of A375-derived tumors compared to those given a vehicle, the addition of CB839 to Vemurafenib treatment had a significant anti-tumor effect. Tumors were taken at the endpoint (Max tumor length 15mm) from the 6 mice in each treatment group and cut into fragments and stored in RNAlater for RNAseq analysis. RNA extraction was performed on 1-3 fragments per tumor to make up 200-300mg of tissue.

2023-04-07 | E-MTAB-12811 | biostudies-arrayexpress

The impact II, a very high resolution quadrupole time-of-flight instrument for deep shotgun proteomics

Project description:Hybrid quadrupole time-of-flight (QTOF) is one of the two major mass spectrometric technologies used in proteomics. Although based on simple fundamental principles, it has over the last decades greatly evolved in terms of achievable resolution, mass accuracy and dynamic range. The Bruker impact platform of QTOF instruments takes advantage of these developments and here we develop and evaluate the impact II for shotgun proteomics applications. Adaption of our heated LC system achieved very narrow peptide elution peaks. The impact II is equipped with a new collision cell with both axial and radial ion ejection, more than doubling ion extraction at high MS/MS frequencies. The new reflectron and detector improve resolving power compared to the previous model up to 80%, i.e. to 40,000 at m/z 1222. We analyzed the ion current from the inlet capillary and found very high transmission (>80%) up to the collision cell. Simulation and measurement indicated 60% transfer into the flight tube. We adapted MaxQuant for QTOF data, improving absolute average mass deviations to better than 1.45 ppm. More than 4,800 proteins can be identified in a single run of HeLa digest in a 90 min gradient. The workflow achieved high technical reproducibility (R2>0.99) and accurate fold change determination in spike-in experiments over three orders of magnitude in complex mixtures. Using label-free quantification we rapidly quantified haploid against diploid yeast and characterized overall proteome differences in mouse cell lines originated from different tissues. Finally, after high pH reversed-phase fractionation we identified 9,515 proteins in a triplicate measurement of HeLa peptide mixture and 11,257 proteins in cerebellum â€“ the highest proteome coverage measured with a QTOF instrument so far.

2015-05-26 | PXD001592 | Pride

Knockdown of DHRS7 in LNCaP cells

Project description:Knockdown of DHRS7 in the prostate cancer cell line LNCaP was performed for 24h, 36h, and 48h using siRNA.

2022-07-07 | PXD031229 | Pride

Strand-oriented RNAseq of LNCaP prostate cancer cells in culture for 48 h in the absence of androgen

Project description:The goal of this study was to use NGS RNAseq deep-sequencing in order to characterize the complement of polyadenylated mRNAs and lncRNAs expressed in LNCaP, a prostate cancer cell line. RNA-seq data were processed as aggregates of the two biological replicates to increase resulting transcriptome coverage. Trimmed reads were mapped with TopHat v.2.0.12 and Bowtie v.2.2.3, and a custom GTF file to guide transcriptome assembly. This custom GTF file was built by using the human transcriptome annotation GTF file downloaded from Ensembl Project web-site (http://www.ensembl.org/) and modified to include all lncRNAs reported in Cabili et al, Genes & Development 2011. polyA+ RNA profiles of LNCaP prostate cancer cell line grown in culture for 48 h in the absence of androgen were generated by paired-end deep sequencing, in duplicate, using Illumina HiSeq2000.

2016-09-08 | E-GEOD-79301 | biostudies-arrayexpress

Expression data from uncastrasion and castration tumor from LNCAP Orhotopic xenograft models of prostate cancer

Project description:To identify molecular singnal alterations between androgen dependent prostate cancer and castration resistant prostate cancer, we performed interspecies comparative microarray analyses using RNAs prepared from uncastrasion and castration tumor from LNCAP Orhotopic xenograft models of prostate cancer. microarray data from uncastrasion and castration tumor revealed that the gene expression profile is most significantly altered in between androgen dependent prostate cancer and castration resistant prostate cancer. Comparative analyses of LNCAP Orhotopic xenograft models of prostate cancer showed that genes involved in androgen dependent and androgen independent tumor were significantly altered. We prepared RNA samples from 4 samples uncastrasion and 4 samples castration tumors from LNCAP Orhotopic xenograft models of prostate cancer . High-quality RNA samples were subjected to microarray analysis using the Affymetrix Human Gene 2.0 ST platform, and only those results that passed examinations for quality assurance and quality control of the Human Gene 2.0 ST arrays were retrieved. In total, we obtained gene expression profiles from the following samples: 4 samples uncastrasion and 4 samples castration tumors

2013-04-20 | E-GEOD-46218 | biostudies-arrayexpress